Compare Dr. Reddys with AJANTA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs AJANTA PHARMA - Comparison Results

DR. REDDYS LAB     Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the pharmaceutical value chain - basic research, finished dosages, generics, bulk actives, and biotechnology. The company's business is mainly organized into Global g... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB AJANTA PHARMA DR. REDDYS LAB/
AJANTA PHARMA
 
P/E (TTM) x 38.0 24.4 155.8% View Chart
P/BV x 5.2 6.8 76.8% View Chart
Dividend Yield % 0.5 0.5 98.1%  

Financials

 DR. REDDYS LAB   AJANTA PHARMA
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-20
AJANTA PHARMA
Mar-19
DR. REDDYS LAB/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs3,3631,422 236.5%   
Low Rs2,352898 262.0%   
Sales per share (Unadj.) Rs1,054.2233.5 451.4%  
Earnings per share (Unadj.) Rs121.944.0 277.3%  
Cash flow per share (Unadj.) Rs190.252.2 364.7%  
Dividends per share (Unadj.) Rs25.009.00 277.8%  
Dividend yield (eoy) %0.90.8 112.7%  
Book value per share (Unadj.) Rs938.7255.1 368.0%  
Shares outstanding (eoy) m166.1788.02 188.8%   
Bonus/Rights/Conversions ESOPBB-  
Price / Sales ratio x2.75.0 54.6%   
Avg P/E ratio x23.426.4 88.8%  
P/CF ratio (eoy) x15.022.2 67.6%  
Price / Book Value ratio x3.04.5 67.0%  
Dividend payout %20.520.5 100.2%   
Avg Mkt Cap Rs m474,831102,081 465.2%   
No. of employees `00021.76.8 318.4%   
Total wages/salary Rs m33,8024,307 784.8%   
Avg. sales/employee Rs Th8,091.03,022.6 267.7%   
Avg. wages/employee Rs Th1,561.3633.4 246.5%   
Avg. net profit/employee Rs Th935.8569.1 164.4%   
INCOME DATA
Net Sales Rs m175,17020,554 852.3%  
Other income Rs m6,206211 2,944.0%   
Total revenues Rs m181,37620,765 873.5%   
Gross profit Rs m24,4215,664 431.1%  
Depreciation Rs m11,348721 1,574.4%   
Interest Rs m98312 8,474.1%   
Profit before tax Rs m18,2965,143 355.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m5610-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-1,4031,273 -110.2%   
Profit after tax Rs m20,2603,870 523.6%  
Gross profit margin %13.927.6 50.6%  
Effective tax rate %-7.724.8 -31.0%   
Net profit margin %11.618.8 61.4%  
BALANCE SHEET DATA
Current assets Rs m125,99111,812 1,066.6%   
Current liabilities Rs m72,1413,776 1,910.3%   
Net working cap to sales %30.739.1 78.6%  
Current ratio x1.73.1 55.8%  
Inventory Days Days7377 94.4%  
Debtors Days Days10582 128.4%  
Net fixed assets Rs m83,85414,398 582.4%   
Share capital Rs m831175 473.8%   
"Free" reserves Rs m155,15722,277 696.5%   
Net worth Rs m155,98822,452 694.8%   
Long term debt Rs m1,3047 19,757.6%   
Total assets Rs m232,25326,962 861.4%  
Interest coverage x19.6444.3 4.4%   
Debt to equity ratio x00 2,843.8%  
Sales to assets ratio x0.80.8 98.9%   
Return on assets %9.114.4 63.5%  
Return on equity %13.017.2 75.4%  
Return on capital %12.623.0 55.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m84,19310,682 788.2%   
Fx outflow Rs m39,6162,102 1,884.8%   
Net fx Rs m44,5778,580 519.6%   
CASH FLOW
From Operations Rs m29,8413,748 796.2%  
From Investments Rs m-4,923-2,228 221.0%  
From Financial Activity Rs m-25,159-1,475 1,706.2%  
Net Cashflow Rs m-26645 -588.5%  

Share Holding

Indian Promoters % 25.5 73.8 34.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.4 1.6 348.4%  
FIIs % 35.3 7.6 464.5%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 17.0 90.0%  
Shareholders   75,885 20,968 361.9%  
Pledged promoter(s) holding % 0.0 4.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   NOVARTIS  TORRENT PHARMA  STRIDES PHARMA SCIENCE  STERLING BIOTECH  ASTRAZENECA PHARMA  

Compare DR. REDDYS LAB With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Flat; Wipro & Hindalco Industries Among Top Nifty Gainers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.

Related Views on News

AJANTA PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 64.2% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 64.2% YoY). Sales on the other hand came in at Rs 7 bn (up 15.0% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 46.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 46.3% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 28.9% (Quarterly Result Update)

Aug 24, 2020 | Updated on Aug 24, 2020

For the quarter ended June 2020, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 7 bn (up 9.2% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 45.3% (Quarterly Result Update)

May 21, 2020 | Updated on May 21, 2020

For the quarter ended March 2020, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 45.3% YoY). Sales on the other hand came in at Rs 7 bn (up 32.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 60.8% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 60.8% YoY). Sales on the other hand came in at Rs 7 bn (up 34.2% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave(Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

An India Revival Stock I'm Bullish On...(Profit Hunter)

Apr 9, 2021

This could take India to the position of 3rd largest economy.

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

A Unique Sector for Short-Term Profits(Fast Profits Daily)

Apr 12, 2021

This ignored sector could deliver big short-term profits.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Apr 16, 2021 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 8-QTR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS